Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
X4 PharmaceuticalsXFOR -2.99%24 Equity-to-Asset is 0.62 as of Mar. 2026, which is 13% above its 10-year median of 0.55. GuruFocus rates XFOR with a GF Score™ of 24/100. The stock has 6 warning signs investors should review. Among 1,416 Biotechnology companies, X4 Pharmaceuticals ranks worse than 57.7% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. X4 Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $168.45 Mil. X4 Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2026 was $270.28 Mil.
Therefore, X4 Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.62.
The historical rank and industry rank for X4 Pharmaceuticals's Equity-to-Asset or its related term are showing as below:
XFOR'
s Equity-to-Asset Range Over the Past 10 Years
Min: -7.44 Med: 0.55 Max: 0.8
Current: 0.62
During the past 11 years, the highest Equity to Asset Ratio of X4 Pharmaceuticals was 0.80. The lowest was -7.44. And the median was 0.55.
XFOR's Equity-to-Asset is ranked worse than 57.7% of 1416
companies
in the Biotechnology industry
Industry Median: 0.68
vs XFOR: 0.62
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
X4 Pharmaceuticals Equity-to-Asset Related Terms
X4 Pharmaceuticals Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for X4 Pharmaceuticals's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XFOR vs CMPX, LRMR, PROK: Equity-to-Asset Comparison
For the Biotechnology subindustry, X4 Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
X4 Pharmaceuticals Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, X4 Pharmaceuticals's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where X4 Pharmaceuticals's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
X4 Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
X4 Pharmaceuticals (XFOR) has a Equity-to-Asset of 0.62 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on X4 Pharmaceuticals and its competitors. This is 13% above median its historical median of 0.55. According to the industry distribution chart, X4 Pharmaceuticals ranks #817 out of 1416 companies in the Biotechnology industry, placing it in the top 57.7%.
Is X4 Pharmaceuticals' Equity-to-Asset too high?
X4 Pharmaceuticals' current Equity-to-Asset of 0.62 is 13% above median its 10-year median of 0.55. The Biotechnology industry median Equity-to-Asset is 0.68. X4 Pharmaceuticals' value of 0.62 is 8.8% below this industry median. Based on the distribution chart, X4 Pharmaceuticals ranks #817 out of 1416 companies in the Biotechnology industry, which is below the industry midpoint. Overall, X4 Pharmaceuticals has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does X4 Pharmaceuticals' Equity-to-Asset compare to CMPX and LRMR?
According to the Biotechnology industry distribution chart, X4 Pharmaceuticals ranks #817 out of 1416 companies for Equity-to-Asset. This places X4 Pharmaceuticals in the lower half of its industry. The industry median Equity-to-Asset is 0.68. X4 Pharmaceuticals' value of 0.62 is 8.8% below this benchmark. While the company's 10-year median is 0.55 vs. the industry median of 0.68, X4 Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. X4 Pharmaceuticals's current Equity-to-Asset of 0.62 is 8.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on X4 Pharmaceuticals and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. X4 Pharmaceuticals's current Equity-to-Asset is 0.62, which is 13% above median its own 10-year median of 0.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is X4 Pharmaceuticals stock overvalued right now?
X4 Pharmaceuticals (XFOR) has a current Equity-to-Asset of 0.62. The current Equity-to-Asset is 0.62, which is 13% above median its 10-year median of 0.55 and 8.8% below the Biotechnology industry median of 0.68. X4 Pharmaceuticals' overall GF Score™ is 24/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For X4 Pharmaceuticals (XFOR), the current Equity-to-Asset is 0.62 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
24GF Score
Get the complete analysis for XFOR
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XFOR has been successfully added to your 
